It is a big bank but has more regulatory issues than the others. He would not own any of the right now. See Utilities for yield. (Analysts’ price target is $62.00)

It is a big generics play. It has been run fairly well over the years. They are reducing debt. It is okay. There is going to be a lot of selling pressure at the $30 level. Quarterly numbers are okay but there is so much out there that is better. He would use a health device and equipment ETF (IHI-N).

He likes medical devices – worldwide hospital spending, changing demographics. It has great tailwinds. They are less politically charged than drug prices.

Utilities. He thinks rates are going higher but less so now. They are not as big a headwind as they could have been. The top three names are renewables. You have better predictability of revenue, which is good in a downturn. They are definitely defensive.

They have 18% top line growth and are killing it in cloud. It has recurring revenue and high growth. It is not trading at a crazy multiple. He thinks it can hang in in a downturn. (Analysts’ price target is $125.69)

A down trend with resistance at $10. It could move back up, but there's nowhere to hang your hat on this chart. There's no base in the price.

Avoided today's sell-off. Chart has a fantastic uptrend since 2014, though it's been oversold and overbought in periods. Current price is just below its January peak. This year it has a cup and handle pattern, which is good. It's not testing its January high. JNJ come be a defensive play, or it could go sideways or even drift down.